USPTO serial 87128871
CANCER
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- GAGLIARDI, JEANINE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CANCER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Camille M. Miller
CAMILLE M. MILLER COZEN O'CONNOR1650 MARKET STREET, Suite 2800One Liberty PlacePHILADELPHIA, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of certain blood diseases and cancers | ACTIVE | — |
| 042 | Development and testing services in the fields of biotechnology, chemistry and pharmaceuticals; scientific study and research in the fields of the prevention, treatment and management of illness, health care delivery and the scientific aspects of health care policy, health care cost management and financing as these fields impact on quality of health care; research in the fields of chemicals and pharmaceuticals; research and testing services in the fields of chemicals and pharmaceuticals; research and development of new products for others in the fields of chemicals and pharmaceuticals; providing clinical laboratory testing services for medical and scientific research and development purposes, namely, pharmacogenetic testing, predictive medical testing, personalized medical testing, gene sequencing-based testing and genotyping based on the assessment, development and application of genomic discoveries in the pharmaceutical, informatics and clinical diagnostic industries; scientific research services; scientific research, namely, development of pharmaceuticals or diagnostic methods for others | ACTIVE | — |
| 044 | Providing on-line information in the field of diagnosis and treatment of cancer; providing an on-line computer database featuring information relating to diagnosis and treatment of cancer; providing medical and pharmaceutical information services; providing links to web sites of others featuring information about the diagnosis and treatment of cancer; providing medical information and pharmaceutical information services, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; health care services, namely, disease management programs that provide counseling and information in the field of pharmaceuticals, and distributing written materials in connection therewith; providing an interactive website featuring medical information that enables users to enter, access, track, monitor and generate health and medical information and reports; providing pharmacogenetic testing, predictive medical testing, personalized medical testing, gene sequencing-based testing and genotyping, all for medical diagnostic and treatment purposes, based on the assessment, development and application of genomic discoveries in the pharmaceutical, informatics and clinical diagnostic industries | ACTIVE | — |
| 045 | Providing information concerning consumer product safety via government pharmaceutical programs that provide counseling and information to medical professionals, pharmacists and patients, particularly counseling and information on consumer product safety issues pertaining to pharmaceuticals, and distributing printed materials in connection therewith | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Celgene Corporation
- Other trademarks owned by Celgene Corporation
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named CANCER
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 28, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 28, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 24, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 23, 2019 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 22, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 19, 2019 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 19, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 24, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 22, 2019 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jan 22, 2019 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 22, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 5, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 19, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 17, 2018 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 17, 2018 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 17, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 25, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 23, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 23, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 23, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 15, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 13, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 13, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 13, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 21, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 24, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 24, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 4, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 12, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 6, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 6, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 6, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 6, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 23, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 23, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 23, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 22, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 22, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 16, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 11, 2016 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 10, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 9, 2016 | NWAP | NEW APPLICATION ENTERED | — |